LUX
Life Sciences
Innovation, patient access and pricing are driving the transformation of the life sciences.
This is a time of enormous disruption in the life sciences sector. New IP being generated and new entrants from the technology industry are accelerating the dawn of personalised medicine.
With a nearly constant stream of capital and emerging technologies, biotech startups have proliferated; investors and Big Pharma are chasing innovations, and drug approvals have hit record levels globally.
Talent acquisition has become a key indicator of future success, with well-funded early stage companies and global pharma companies competing on an increasingly level playing field.
Luxembourg
Life sciences in Luxembourg represent an emerging and fast-evolving market. Strong financial and political support has resulted in the development of public research centres, the research-oriented University of Luxembourg, biotech companies, as well as a proliferation of private laboratories and foundations.
Therefore, the life sciences sector is facing important challenges, including attracting and retaining a highly-skilled and multicultural workforce.
At Odgers Berndtson Luxembourg, our team supports biotechnology companies and research centres on developing boards and executive teams.
